This roundtable series evaluates the use of combination therapies using immunotherapy and chemotherapy in patients with advanced Hodgkin lymphoma, as discussed by key opinion leaders and participants at virtual live events.

Patients With Advanced Hodgkin Lymphoma Treated Using Frontline Immunotherapy Plus Chemotherapy

Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

May 24, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.

Considerations for Frontline Treatment of Advanced Hodgkin Lymphoma

March 29, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the history of the use of brentuximab vedotin in Hodgkin lymphoma and how to evaluate patients after primary therapy.